204452-37-9

Upstream product

• 174665-68-0 ethyl 4-[2-(2-aminopyridin-6-yl)ethynyl]benzoate 
• 150969-54-3 ethyl 4-(trimethylsilylethynyl)benzoate 
• 51934-41-9 4-iodobenzoic acid ethyl ester 
• 10602-03-6 ethyl 4-ethynylbenzoate 
• 19798-81-3 2-Amino-6-bromopyridine 

Downstream Products

• 298692-94-1 4-[2-(2-aminopyridin-6-yl)ethyl]benzoic acid 
• 204452-38-0 4-[2-(2-Aminopyridin-6-yl)ethyl]benzoic acid hydrochloride 
• 204452-39-1 3-{4-[2-(6-aminopyridin-6-yl)ethyl]benzoylamino}-2(S)-4-iodobenzenesulfonylaminopropionic acid ethyl ester 
• 298692-95-2 3-[4-(2-aminopyridin-6-ylethyl)benzoylamino]-2(S)-benzenesulfonylaminopropionic acid tert-butyl ester 
• 204452-40-4 3-{4-[2-(2-aminopyridin-6-yl)ethyl]benzoylamino}-2(S)-4-iodobenzenesulfonylamino-propionic acid 
• 801239-56-5 3-{4-[2-(6-{2-[2-(3-tert-butoxycarbonylamino-propoxy)-ethoxy]-ethylamino}-pyridin-2-yl)-ethyl]-benzoylamino}-2-(2,4,6-trimethyl-benzenesulfonylamino)-propionic acid 
• 801239-97-4 4-[2-(6-{2-[2-(3-tert-butoxycarbonylamino-propoxy)-ethoxy]-ethylamino}-pyridin-2-yl)-ethyl]-benzoic acid 

Relevant academic research and scientific papers

Chemical adaptor immunotherapy: Design, synthesis, and evaluation of novel integrin-targeting devices

A series of β-diketone derivatives of RGD peptidomimetics that selectively bind to αvβ3 and αvβ5 integrins were synthesized and covalently docked to the reactive lysine residues of monoclonal aldolase antibody 38C2. The resulting targeting devices strongl

Dibenzoxazepine alpha v integrin receptor antagonist

The present invention relates to a novel dibenzoxazepine derivative, its synthesis, and its use as an αv integrin receptor antagonist. More particularly, the compound of the present invention is an antagonist of the integrin receptors αvβ3 and αvβ5 and th

Alpha v integrin receptor antagonists

The present invention relates to novel chain-fluorinated alkanoic acid derivatives thereof, their synthesis, and their use as αv integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin recep

Alpha v integrin receptor antagonists

The present invention relates to cyclic urea derivatives, their synthesis, and their use as αv integrinreceptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors αvβ3 and αvβ15 and are useful

Alpha V integrin receptor antagonists

The present invention relates to novel imidazolidinone derivatives thereof, their synthesis, and their use as αv integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors αvβ3 and/or

Alpha V integrin receptor antagonists

The present invention relates to novel compounds formed by metabolic conversion of compounds of the structural formula depicted below (R═H or Me), pharmaceutical compositions containing such compounds, and their use as αvβ3 integrin receptor antagonists.

Alpha v integrin receptor antagonists

The present invention relates to novel compounds formed by metabolic conversion of compounds of structural formula (1), pharmaceutical compositions containing such compounds, and their use as αvβ3 integrin receptor antagonists. The compounds of the presen

αv integrin receptor antagonists

The present invention relates to novel nonanoic acid derivatives, their synthesis, and their use as αv integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors αvβ3 and αvβ5 and are

Integrin receptor antagonists

The present invention relates to compounds and derivatives thereof, their synthesis, and their use as vitronectin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors αvβ3 and/or αvβ5 an

Method for eliciting an αvβ5 or dual αvβ3/αvβ5 antagonizing effect

A method for eliciting an αvβ5or dual αvβ3/αvβ5antagonizing effect in a mammal which comprises administering to the mammal a therapeutically effective amount of a compound of the formula which are useful for inhibiting restenosis, angiogenesis, atherosclerosis, diabetic retinopathy, macular degeneration, inflammation or tumor growth.